713P Pembrolizumab (Pembro) vs placebo (Pbo) as second-line treatment for sorafenib-treated advanced hepatocellular carcinoma (aHCC): 4.5-year follow-up from KEYNOTE-240

J Edeline,R.S Finn,M Bouattour,A-L Cheng,S.L Chan,T Yau,M Garrido,J Knox,B Daniele,V Breder,H.Y Lim,S Ogasawara,A Odeleye-Ajakaye,I Martinez-Forero,A.B Siegel,P Merle

doi:10.1016/j.annonc.2022.07.837

713P Pembrolizumab (Pembro) vs placebo (Pbo) as second-line treatment for sorafenib-treated advanced hepatocellular carcinoma (aHCC): 4.5-year follow-up from KEYNOTE-240

J Edeline, R.S Finn + Show 14 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.837

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
Citations: 1	License type: publisher-specific-oa

Affiliation: National Taiwan University, University of Hong Kong, Princess Margaret Cancer Centre, National Medical Research Center of Cardiology, Sungkyunkwan University, Chiba University

#Benefit In OS #Improvements In OS + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Pembro demonstrated promising ORR in sorafenib-treated patients (pts) with aHCC in KEYNOTE-224, leading to accelerated regulatory approval in the US. KEYNOTE-240 showed a similar ORR and clinically meaningful improvements in OS and PFS, although prespecified statistical significance criteria for OS and PFS were narrowly missed. KEYNOTE-394 demonstrated statistically significant and clinically meaningful benefit in OS, PFS, and ORR with pembro vs pbo in pts from Asia with sorafenib or oxaliplatin-based chemotherapy treated aHCC.

Full Text